New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 1, 2006, Pages 41-47

  Pree, Ines ^a   Wekerle, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABI 793; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; BG 9588; BMS 224819; CD28 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HUC 58; IMMUNOSUPPRESSIVE AGENT; LEA 29 Y; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RUPLIZUMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR IMMUNITY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33645890847     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.02.002     Document Type: Review

References (53)

1. Groth C.G. Presidential address 2002: organ transplantation as a patient service worldwide. Transplantation 79 (2003) 1098-1100
2. Nankivell B.J., et al. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349 (2003) 2326-2333
3. Ojo A.O., et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349 (2003) 931-940
4. Kasiske B.L., et al. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. 3 (2003) 178-185
5. Kotloff R.M., and Ahya V.N. Medical complications of lung transplantation. Eur. Respir. J. 23 (2004) 334-342
6. Kasiske B.L., et al. Cancer after kidney transplantation in the United States. Am. J. Transplant. 4 (2004) 905-913
7. Duncan M.D., and Wilkes D.S. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc. Am. Thorac. Soc. 2 (2005) 449-455
8. Wekerle T., et al. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr. Opin. Immunol. 14 (2002) 592-600
9. Rothstein D.M., and Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196 (2003) 85-108
10. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2 (2002) 116-126
11. Blair P.J., et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J. Exp. Med. 191 (2000) 651-660
12. Watts T.H., and DeBenedettet M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11 (1999) 286-293
13. Greenwald R.J., et al. CTLA-4 regulates induction of anergy in vivo. Immunity 14 (2001) 145-155
14. Finger E.B., and Bluestone J.A. When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat. Immunol. 3 (2002) 1056-1057
15. Bluestone J.A. CTLA-4Ig is finally making it: a personal perspective. Am. J. Transplant. 5 (2005) 423-424
16. Lenshow D.J., et al. Long-term survival of xenogeneic pancreatic islets induced by CTLA4Ig. Science 257 (1992) 789
17. Linsley P.S., et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257 (1992) 792-795
18. + cells. Am. J. Transplant. 1 (2001) 339-349
19. Kirk A.D., et al. The role of CD154 in organ transplant rejection and acceptance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 (2001) 691-702
20. Elster E.A., et al. The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transpl. Immunol. 13 (2004) 87-99
21. Larsen C.P., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
22. Kirk A.D., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U S A 94 (1997) 8789-8794
23. Kirk A.D. Crossing the bridge: large animal models in translational transplantation research. Immunol. Rev. 196 (2003) 176-196
24. Wekerle T., et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J. Exp. Med. 187 (1998) 2037-2044
25. Wekerle T., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. 6 (2000) 464-469
26. Wekerle T., and Sykes M. Mixed chimerism and transplantation tolerance. Annu. Rev. Med. 52 (2001) 353-370
27. Kirk A.D., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5 (1999) 616-617
28. Sidiropoulos P.I., and Boumpas D.T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13 (2004) 391-397
29. Dall'Era M., and Davis L. CTLA4Ig: a novel inhibitor of costimulation. Lupus 13 (2003) 372-376
30. Schuler W., et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77 (2004) 717-726
31. Kenyon N.S., et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 48 (1999) 1473-1481
32. Pierson R.N.I., et al. Prolongation of primate cardiac allograft survival by treatment with anti-CD40 ligand (CD154) antibody. Transplantation 86 (1999) 1800-1805
33. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant. 2 (2002) 898-903
34. Boumpas D.T., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48 (2003) 719-727
35. Pfeiffer S., et al. Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation. J. Heart Lung Transplant. 20 (2001) 250
36. Kawai T., et al. Thromboembolic complications after treatment with monoclonal antibody. Nat. Med. 6 (2000) 114
37. Koyama I., et al. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 77 (2004) 460-462
38. Andre P., et al. CD40L stabilizes arterial thrombi by a [beta]3 integrin-dependent mechanism. Nat. Med. 8 (2002) 247-252
39. Kremer J.M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349 (2003) 1907-1915
40. Abrams J.R., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103 (1999) 1243-1252
41. Genovese M.C., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353 (2005) 1114-1123
42. Larsen C.P., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5 (2005) 443-453
43. Adams A.B., et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 51 (2002) 265-270
44. Vincenti F., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353 (2005) 770-781
45. Czuczman M.S., et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23 (2005) 4390-4398
46. Tan P., et al. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169 (2002) 1119-1125
47. Kirk A.D., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72 (2001) 377-384
48. Ossevoort M.A., et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 68 (1999) 1010-1018
49. Adams A.B., et al. Development of a chimeric Anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174 (2005) 542-550
50. Pluvinet R., et al. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 104 (2004) 3642-3646
51. Hwang K.W., et al. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J. Immunol. 169 (2002) 633-637
52. Matthews J.B., et al. Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. 3 (2003) 794
53. Bluestone J.A. CTLA-4Ig is finally making it: a personal perspective. Am. J. Transplant. 5 (2005) 423-424